Clinical trials: Headache Disorder
Headache, Tension-Type
A Pharmacokinetic Study of an Experimental Paracetamol Formulation
This PK study is designed to show bioequivalence between the study treatments.
- Trial name
- NCT01476176
- Testing
- Experimental paracetamol, Paracetamol marketed formulation
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
This study is being conducted to determine the appropriate dose of rimegepant in Japanese subjects, as well as to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the acute treatment of…
- Trial name
- NCT05399459
- Testing
- Rimegepant 25 MG, Rimegepant 75 MG
- Where
- 50 sites in Japan
- Volunteers
- 897 people
- Sponsor
- Pfizer
Migraine
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- Trial name
- NCT04804033
- Testing
- BHV-3500 (zavegepant)
- Where
- 116 sites in United States
- Volunteers
- 1,753 people
- Sponsor
- Pfizer
Migraine Disorders
An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)
This study will evaluate the exposure of sumatriptan after administration of TREXIMA (sumatriptan 85mg/naproxen sodium 500mg) followed by a subcutaneous IMITREX injection (4mg or 6mg) 2 hours later compared to administration of a…
- Trial name
- NCT00875784
- Testing
- TREXIMA™, IMITREX® (4mg), IMITREX® (6mg)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Migraine
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
The purpose of this multi-center, prospective, double-blind, randomized, sham-controlled pilot study is to study feasibility and collect preliminary clinical data related to the safety and clinical benefits of daily use of…
- Trial name
- NCT01667250
- Testing
- GammaCore Active Device
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- ElectroCore INC
Migraine, Episodic Migraine
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
- Conditions
- Migraine, Episodic Migraine, Phonophobia, Photophobia
- Trial name
- NCT05207865
- Testing
- Rimegepant
- Where
- 19 sites in United States
- Volunteers
- 441 people
- Sponsor
- Pfizer
Migraine
A Proof of Concept Alleviating the Symptoms of Photosensitive Migraine.
This proof of concept clinical study will investigate the efficacy of active lens with frame in alleviating the symptoms of migraine which are caused by photosensitivity.
- Trial name
- NCT04904328
- Testing
- Lumishade® Active Lens
- Volunteers
- 77 people
- Sponsor
- Mitsui Chemicals, Inc.
Migraine
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine.
- Trial name
- RELIEF (NCT04384367)
- Testing
- Rizatriptan 10 mg + Naproxen 550mg, Maxalt 10Mg Tablet, Flanax 550mg
- Where
- 2 sites in Brazil
- Volunteers
- 2,068 people
- Sponsor
- Eurofarma Laboratorios S.A.
Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
- Trial name
- PIONEER-PEDS1 (NCT04396236)
- Testing
- Lasmiditan
- Where
- 152 sites in United States, Belgium and 13 more
- Volunteers
- 847 people
- Sponsor
- Eli Lilly and Company
Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03939312
- Testing
- Atogepant
- Where
- 113 sites in United States
- Volunteers
- 685 people
- Sponsor
- Allergan
Epilepsy
Study on Migraine and Headache in Epileptic Patients
The purpose of this study is to collect data from patients who are diagnosed with epilepsy and are followed up in epilepsy clinics.
- Trial name
- NCT00642564
- Testing
- Observational study in Epileptic Patients
- Volunteers
- 955 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Headache (Migraine)
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of…
- Trial name
- NCT00293657
- Testing
- Lornoxicam 8 mg, Lornoxicam 16 mg
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- POZEN
Migraine
Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis
The purpose of this study is to evaluate the efficacy of botulinum toxin type A (Dysport®) injections into pericranial muscles compared to placebo to prevent migraine attacks.
- Trial name
- NCT00301665
- Testing
- Botulinum toxin type A
- Where
- 9 sites in Czechia, Poland and 1 more
- Volunteers
- 138 people
- Sponsor
- Ipsen
Migraines
A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250
A trial to assess the efficacy, safety, tolerability and effect of a drug (code name TRV250) given as an injection to subjects who have received an injection of a drug called glyceryl trinitrate (GTN) which is clinically known to…
- Trial name
- NCT04201080
- Testing
- Part A: TRV250-20mg/ml, Part B: TRV250 Dose 1, Part B: TRV250 Dose 2
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Trevena Inc.
Migraine
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
- Trial name
- NCT03934086
- Testing
- rimegepant
- Sponsor
- Pfizer
Migraine
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment…
- Trial name
- NCT04530110
- Testing
- Fremanezumab
- Where
- 70 sites in United States, Canada and 7 more
- Volunteers
- 499 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Migraine Disorders, Chronic Migraine Headache
EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine
EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine…
- Conditions
- Migraine Disorders, Chronic Migraine Headache, Migraine
- Trial name
- EMBRACE-OBS (NCT07652034)
- Testing
- Middle Meningeal Artery Embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cortex Neurovascular
Migraine
Fremanezumab Managed Access Program for Pediatric Patients
This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either…
- Trial name
- NCT03539393
- Testing
- Fremanezumab
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Migraine
A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.
This is a double-blind randomised controlled study to evaluate the effectiveness of orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and duration of migraines in otherwise healthy…
- Trial name
- NCT05046522
- Testing
- Palmitoylethanolamide sold as Levagen +
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- RDC Clinical Pty Ltd
Migraine
A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
This is a single-center, open-label, randomized, four-way crossover study. Subjects will receive the four study treatments once, followed by in-clinic monitoring and extensive pharmacokinetic analysis.
- Trial name
- NCT03978403
- Testing
- M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches), M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups), M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zosano Pharma Corporation